Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Seagen - Case by Case: Strategic Sequencing Considerations in 3L HER2+ Metastatic Breast Cancer (MBC)

Decision-making in 3L Following T-DXd Progression (Case-based discussion)

Date

23 Oct 2023

Session

Seagen - Case by Case: Strategic Sequencing Considerations in 3L HER2+ Metastatic Breast Cancer (MBC)

Topics

Tumour Site

Breast Cancer

Presenters

Joyce O'Shaughnessy

Authors

J. O'Shaughnessy

Author affiliations

  • Texas Oncology - Baylor Sammons Cancer Center, 75246 - Dallas/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and Introductions

Presenter: Cristina Saura Manich

Session: Seagen - Case by Case: Strategic Sequencing Considerations in 3L HER2+ Metastatic Breast Cancer (MBC)

Resources:

Webcast

Q&A

Presenter: All Speakers

Session: Seagen - Case by Case: Strategic Sequencing Considerations in 3L HER2+ Metastatic Breast Cancer (MBC)

Resources:

Webcast

Closing Remarks

Presenter: Cristina Saura Manich

Session: Seagen - Case by Case: Strategic Sequencing Considerations in 3L HER2+ Metastatic Breast Cancer (MBC)

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.